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In October 2013, US cell biologist Randy W. Schekman (Saint Paul, Minnesota, USA, 
1948) won the Nobel Prize in Physiology or Medicine together with James E. Rothman 
and Thomas C. Südhof, in recognition for their contributions to our understanding of the 
machinery regulating cell membrane vesicle traffic. In the same week the medals were 
awarded, Schekman expressed his highly critical views about the prevailing structures 
for publishing and rewarding science. Writing in The Guardian, he announced that the 
laboratory he runs at the University of California, Berkeley, would no longer send re-
search papers to be published in three of the leading—and commonly regarded as the 
most prestigious—scientific journals, namely, Cell, Nature, and Science [14].
Basic science, “luxury journals”
Schekman can be considered one of the founding fathers of modern cell biology. Many 
of the basic premises governing this discipline, which we now take for granted, were 
established through the work carried out in his lab [3]. He received his PhD in 1975 from 
Stanford University, working on DNA replication under the direction of 1959 Nobel lau-
reate Arthur Kornberg. The year after, he moved to the University of California, Berkeley 
[7]. There he began studying cells of the yeast Saccharomyces cerevisiae that had mal-
functions in their cell transport system and demonstrated that these were caused by 
genetic defects. In doing so, he managed to dissect the mechanics of vesicle formation 
and explain how different genes regulate different aspects of cell transport. In other 
words, how molecules inside vesicles are delivered to the right place at the right time 
[7,10,11,19].
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Because nearly all of the vesicle traffic steps are encoded 
by highly-conserved genes, Schekman and colleagues’ pio-
neering work led to the development of tools to study other 
types of cells. It turned out that some of the genes Schekman 
had discovered in yeast were also present in mammals, encod-
ing the corresponding proteins and thus “revealing an ancient 
evolutionary origin of the transport system” [3,11]. As a result, 
according to the committee of the Dickson Prize in Medicine, 
an award he received in 2008, “it is nearly impossible to attend 
a large meeting in cell biology, biochemistry, genetics or mo-
lecular biology and not hear someone mention a homolog of 
one of the genes discovered by the Schekman lab” [3].
Schekman’s scientific pursuits have resulted in the publica-
tion of over 250 papers, many of them in leading scientific 
journals (Fig. 1). However, he is not only well known for his 
research, but also—especially over the last few years—for his 
engagement in the Open Access movement. And he is using 
the newfound prominence that invariably comes alongside a 
Nobel Prize to urge the scientific community to reconsider 
where and how they choose to publish their most important 
research [9]. He wrote: “I have published in the big brands, in-
cluding papers that won me a Nobel Prize. But no longer.” And 
added: “Just as Wall Street needs to break the hold of bonus 
culture, so science must break the tyranny of the luxury jour-
nals” [14].
By “luxury journals” he is referring to certain leading aca-
demic journals that, in his opinion, have distorted how sci-
ence and scientists operate by limiting publication to artifi-
cially low numbers. Schekman’s two main criticisms of such 
journals are as follows. First, he argues that, by following a 
print-based business model, journals such as Cell, Nature, 
and Science restrict the number of papers they accept. In the 
21st century, with more and more research being made avail-
able, distributed, and read online, these limitations are fabri-
cated and lack of space is a meaningless argument—but lux-
ury journals know that scarcity fuels demand. However, 
Schekman compares their position to that of “fashion design-
ers who create limited-edition handbags” and points out that 
their behavior contributes more to the selling of subscrip-
tions than to the publishing of the best research [14]. 
This relates to his second denunciation, that science as a 
whole is being distorted by the incentives offered by the top 
journals. In particular, he criticizes the “Impact Factor” (IF), a 
widespread metric that measures a journal’s quality by calcu-
lating how often recently published papers in that journal are 
cited on average. Originally designed by Eugene Garfield as a 
means to compare different journals within a certain field 
and help scientists choose where to publish [5, 6,18], the im-
pact factor is now often used inappropriately, for example, to 
evaluate the quality or influence of individual pieces of re-
search or to assess researchers [16]. Schekman argues that 
impact factors can introduce biases, for example, because “a 
paper can become highly cited because it is good science—or 
because it is eye-catching, provocative, or wrong” [14].
Furthermore, he adds that while luxury journals “publish 
many outstanding papers, they do not publish only outstand-
Fig. 1. Randy W. Schekman, 2013 Nobel Prize in Physiology or Medicine. (©Miguel Lorenzo, Valencia)
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ing papers. Neither are they the only publishers of outstand-
ing research” [14]. However, scientists remain under huge 
pressure, from universities, grant committees and funding 
agencies, to publish in these high-IF journals, and this, he be-
lieves, is corrupting the nature of scientific enquiry. 
Accordingly, Schekman was one of the first signatories of 
the San Francisco Declaration on Research Assessment (DORA). 
Written during an Annual Meeting of the American Society for 
Cell Biology in December 2012, this set of recommendations 
represents a serious and determined initiative, championed by 
scientists and research institutions from around the world, 
that demands a change in the ways in which the output of sci-
entific research is evaluated by funding agencies, academic 
institutions, and other parties [1]. 
Schekman also encourages scientists to make their research 
more accessible by publishing it online and by choosing Open 
Access journals [14] that are freely available for anyone to read 
(Fig. 2). A former editor-in-chief of the Proceedings of the Na-
tional Academy of Sciences of the USA [19], Schekman is cur-
rently the founder and editor-in-chief of eLife [www.elifescienc-
es.org]. This online, peer-reviewed, Open Access journal for 
biomedical and life sciences was founded in 2012 with sponsor-
ship from the Howard Hughes Medical Institute (USA), the Max 
Planck Society (Germany), and the Wellcome Trust (UK). The 
journal tackles many of the criticisms Schekman makes of luxu-
ry journals: they are a unique, non-profit, researcher-driven 
initiative (thanks to the financial support of the three founda-
tions backing the project); decisions to publish are made quick-
ly (with an average of 90 days from submission to acceptance), 
and they work to expand and enrich the concept of research 
impact beyond the IF. Furthermore, articles are published in full 
length and the editorial board endeavors to cover the broad 
spectrum of the life sciences, with no bias in favor of what 
might be considered “glamourous” areas [12]. 
***
On 3 June 2014, University of Valencia’s Mètode magazine 
[www.metode.cat] and its Two Cultures Observatory [http://
metode.cat/Les-dues-cultures], devoted to the study of the 
relationship between scientists and the media, interviewed 
Randy W. Schekman in Valencia. Despite his affable look and 
permanent smile, Schekman’s is passionate about his mis-
sion and profoundly critical of the system it seeks to replace. 
You claim that scientific publications such as Nature, Cell, or 
Science distort the reality of scientific research. But these jour-
nals remain the most respected in the scientific community.
Yes, they have a very effective business plan, I would say. 
They prey on people’s vanity. People like to be part of an ex-
clusive club and this is what these journals encourage by be-
ing very selective in what they choose to review. They look 
for things they think will be hot topics, you know, bestsellers. 
And then, even after they agree to review a paper, they im-
pose increasing demands on the author to modify things, to 
somehow make it even more perfect. They consult with a 
large number of people, and they go through the paper over 
and over again—a process that can sometimes take over a 
year—and in the end, they may decide to reject the paper 
after all. This creates an enormous effort and added expense 
before the paper gets published, which I believe is a toxic in-
fluence. It causes a delay in the publication of science.
Some months ago you announced that you will not publish 
in those journals, but you have prestige…
Well, yes... I have been saying this for a long time. I actually 
haven’t published my own primary research in these journals 
for some years now. I also voiced my thoughts about the im-
pact factor during the five years I was the editor of the Pro-
ceedings of the National Academy of Sciences of the USA, and 
the press never interviewed me about my position back then. 
But I won a Nobel Prize and now I have a louder voice. And I 
intend to use that voice to express my opinion.
Would it be as easy for researchers who are just starting 
their careers to refuse to publish in these journals?
 
Yes, they just have to have the courage to stand by their con-
victions. There are young researchers who have completely 
avoided publishing in them. We have a young scholar at 
Berkeley, Michael Eisen, an expert in genome analysis who 
was one of the original editors of the PLoS (Public Library of 
Science) journals. He has taken a very strong position against 
what he calls the “glamour journals,” and he has never pub-
lished in them. And yet he has had a very successful career, 
becoming a researcher at the Howard Hughes Medical Insti-
tute (Chevy Chase, MD, USA). He is very bright and he is very 
successful. And he has realized that one doesn’t need to play 
these journals’ game in order to publish important work.
Does his institution support him in this decision?
 
Yes, absolutely, absolutely. In fact, at Berkeley, because of his 
position and because of my position, more and more of our col-
leagues are submitting their papers to open-access journals. Of 
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course, they continue to publish in Cell, Nature, and Science as 
well. But I think that increasingly, at Berkeley, we understand 
that the discussions about what one publishes in this or that 
journal have to give way to the real evaluation of knowledge. 
In open-access journals, the author must pay to publish. 
Do you think that is a conflict of interest?
 
I mean that maybe it can give rise to a different kind of bias, 
sidelining groups with lower budgets.
Yes, well, but remember that in many commercial jour-
nals, you have to pay to publish too. In eLife, however, we 
do not charge anything. It is completely subsidized for the 
time being.
But this is not the most common situation.
No, it’s not. I think we have an advantage, and I intend to 
make the most out of it.
Some months ago, John Bohannon, a journalist writing for 
Science, sent a fake paper—full of mistakes—to more than 
300 open-access journals and 60 % of them accepted it. 
All those journals were open-access, yes… But he might as 
well have sent it to all the commercial journals too...
Are Open Access journals less rigorous?
The question is not whether they are Open Access or not. This 
is a false distinction. There are other journals that are commer-
cial or run by scientific societies that may also have low stan-
dards. And I do not think that just because a journal is open-
access, this makes it somehow more suspicious. It is true that 
there are businesses out there looking to exploit the Open Ac-
cess movement to make money, and the buyer must be aware. 
As I said earlier, if you want to publish in one of these new 
journals, look at the composition of the editorial board and see 
who is actually putting their time in to make it a successful 
venture. This should be the deciding factor.
Is it sustainable to have so many scientific publications? Do 
you think we are faced with a bubble that could burst at any 
moment?
Before the Open Access movement there already were thou-
sands of titles, there were many journals. Now, it is tough to 
survive because libraries have budget cuts and they have to 
look very carefully at what they subscribe to, or what they get 
licenses for. And it is possible that many journals will disap-
pear, but maybe this is a good thing.
 
What is the role of the Internet in the increasing number of 
journals?
Oh, it’s crucial. I mean, it signifies a complete change in the 
way that we read things. Most young scholars do not even 
peruse journals anymore; a hard copy of a journal is like a 
dinosaur. And the only reason why Nature and Science con-
tinue to flourish is because people want the journal to read 
the ‘front half’ sections, as opposed to the ‘back half” where 
the research is found. People read the current scientific 
events, not so much the papers. As a matter of fact, reading 
a paper in Nature or Science is a very unpleasant experience. 
Really?
Yes, because it is like a tiny little advertisement of the actual pa-
per. For most research published in Science today, the bulk of the 
paper is relegated to the supplementary material, which is only 
available online and not in print. When you submit a paper to 
Nature or Science, it is normally a full paper. And if you manage to 
get it accepted, they will usually tell you to cut out most of the 
stuff and include it in the supplementary information. And again, 
this is because their model is based on the print version and they 
are trying to save money on the print. For me, this is a complete-
ly artificial commodity in the 21st century. They should not be 
doing this. Papers should all be available online in the full form so 
that people can read them.
A great deal of papers are not read and many experiments 
are not replicated. Without confirmation and the subse-
quent debate, where does all this knowledge go?
We have a problem. Some people claim that important pa-
pers cannot be replicated. In my opinion, this is the argu-
ment used by pharmaceutical companies who make obser-
vations in the scientific literature but then cannot repro-
duce the results. But I wonder whether they are really try-
ing to reproduce these experiments or they are simply try-
ing to develop a drug in an animal model without repeating 
the experiments described in the publication exactly. It is 
unknown what fraction of the literature is wrong, so we are 
conducting an experiment. We have been approached by an 
organization called the Reproducibility Project, where a pri-
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vate foundation has agreed to fund experiments to repli-
cate fifty high-impact papers in cancer biology published 
between 2010 and 2012, and the work will be carried out 
independently by a network of expert labs (to learn more, 
visit The Reproducibility Project: Cancer Biology [https://
osf.io/e81xl/wiki/home/]). We have agreed to handle this 
and eventually publish the reproducibility studies in eLife, 
so we will know, at least for these fifty papers, how many of 
them are really reproducible. We are just getting started 
with this, so it may be a couple of years, but it’s what we’d 
like to do. 
How did your life change after the Nobel Prize?
I get interviewed by the press much more. I travel a bit more… 
people somehow listen to me more than they used to. Unfor-
tunately, the downside is that I have less time to spend in my 
lab. That is the downside, that I have less time for my lab and 
my life is much more hectic. I hope that everything will go 
back to some normality, perhaps in a year or so. 
In Mètode, we started the Two Cultures Observatory [http://
metode.cat/en/The-Two-Cultures-Observatory] in order to 
analyze the relationship between science and the media. 
Do you think that science publications set the agenda for 
the general media?
Yes, this is a problem that has developed over the years. 
There used to be many more science journalists, hired by 
newspapers, who would look at the papers published in vari-
ous journals. But increasingly, unfortunately, these newspa-
pers have fired, gotten rid of their science journalists. So now 
many newspapers are dependent on the press releases is-
sued by the journals themselves to describe the work they 
publish, and this may be good for the journals, but I don’t 
think it is good for the general public.
The number of papers has increased a lot. How can a jour-
nalist find what is really interesting without being influ-
enced by the journals or the research groups?
Well, it’s tough. That is why it is important to have science jour-
nalists working in newspapers who have the time to go and 
read the literature. I agree that it is a daunting task, though.
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Fig. 2. Covers of different publications: subscription journals (upper row), and open-access-only journals (lower row).
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Some scientists consider that journalists are too sensation-
alist, but can the scientists themselves sometimes exagger-
ate their research?
Oh, absolutely. In order to get their papers published in Na-
ture or Science they exaggerate the importance of their work, 
absolutely. Researchers are under pressure to get their work 
funded and so they think that if they get more publicity for 
their work, even in the media, this will help them obtain fund-
ing, or help them attain recognition, fame and glory. I mean, 
why should scientists be any different than other people?
 
And what do you think about media coverage of cell biology?
It does not get much attention. Science journalists tend to 
focus on research related to health and disease, or on discov-
eries such like planets and satellites in other planetary sys-
tems. Unfortunately, I find most science articles in newspa-
pers unsatisfying, even those in leading publications such as 
The New York Times. Let’s say that a journalist talks about the 
discovery of a new drug for cancer, a topic that interests me. 
Generally, he or she does not say anything about how the 
drug works—its mechanism of action—and I find this very 
discouraging, because that is what I really care about, that is 
what science is. But I suppose they feel that for most people, 
for the majority of readers, that would be too much informa-
tion. 
Could you explain in layman terms, if possible, the impor-
tance of vesicle traffic in our cells?
Sure. Our genome encodes around 23,000 genes. That 
means that our cells manufacture at least that number of 
protein molecules. Proteins are the molecules that catalyze 
the chemistry of life, they are all the little machines in our 
cells that allow them to grow and divide. And all the proteins 
in a cell are manufactured inside it, but some have to be 
shipped outside of the cell, like insulin, growth factors or the 
proteins in your blood. However, there is a barrier—the cell 
is surrounded by a membrane—and proteins like insulin, 
which are water-loving molecules, cannot just swim through 
the membrane, which is a water-hating barrier that doesn’t 
allow soluble proteins to just go through. 
So the proteins that are going to be transported outside 
of the cell, such as antibodies, have to be encapsulated in-
side the cell by little carriers called vesicles. And these carri-
ers transport proteins like insulin up to the cell surface and 
then the vesicle, which is a membrane itself, merges with the 
cell membrane by a process known as “membrane fusion.” 
When that happens, the inside of the vesicle becomes the 
outside of the cell, this special compartment opens and its 
contents are poured outside the cell. This is what is called 
“secretion” and cells execute this pathway through “vesicular 
traffic.” And this is responsible for all secretion from all cells, 
not only protein molecules but also brain neurotransmitters 
are secreted through this same pathway. 
What we discovered was that yeast cells use the same 
mechanism to grow and we devised a genetic approach to 
isolate and identify the genes that organize the process, and 
it turns out that these genes are the same in humans. The 
very same genes that allow a yeast cell to secrete its proteins 
are the genes in the human genome that allow the secretion 
or the transport of neurotransmitters.
***
As evidenced by Schekman’s skills in explaining his own re-
search, he also believes that to communicate effectively with 
a broader public is a scientist’s responsibility. Following this 
idea, another interesting addition to every paper published 
in eLife, the journal he edits, is the ‘eLife digest’ an accompa-
nying text written for a broader audience in which most of 
the technical language is removed. It is aimed at people who 
might be interested in that piece of research, but who have 
only a basic understanding of life sciences [8]. At the moment 
is it mainly the editors who are in charge of this section, but 
there is hope is, the scientists carrying out the research will 
eventually take over this task themselves.
How to break free 
Schekman’s criticisms of luxury journals have not gone with-
out comment. Monica Bradford, executive editor of Science, 
said that there is nothing artificial about their acceptance 
rates—they are just a reflection of the journal’s scope and 
mission. Emilie Marcus, editor of Cell, explained that their 
raison d’être is to serve science and scientists, and offering 
value to both their authors and readers was a founding prin-
ciple, not a luxury [13]. Philip Campbell, editor-in-chief of Na-
ture, pointed out a longstanding relationship with the scien-
tific community of over 140 years. He acknowledged that the 
research community tends towards an over-reliance of as-
sessing research by the journal in which it appears, but he 
also maintained that he and his colleagues have for years ex-
pressed their concerns about the dependence on IFs [13,17]. 
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However, as Stephen Curry, Professor of Structural Biology at 
Imperial College London, pointed out, “it is not sufficient to 
lay the problem at the feet of the research community when 
journals are part of that community” [2].
Schekman agrees that journals are only half of the equa-
tion. The demand for luxury journals also has to be addressed 
by the researchers themselves and by the institutions that 
use them to judge scientific quality. Writing in The Conversa-
tion he suggests four ways in which we can start to remove 
the incentives that make it rational to publish under the big-
gest brands:
1. Academics who participate in research assessment 
could shun all use of journal names and IFs as a surrogate 
measure of quality. New practices and processes must be 
devised and shared so that we can rapidly move forward. 
His Berkeley colleague Michael Eisen has added an im-
portant point: we must speak up in appointment and 
funding committees when we hear others use journal 
names this way. Here we need peer pressure as much as 
we need peer review [4].
2. Researchers applying for positions, funding, and tenure 
should avoid any mention of IFs in their applications or 
CVs. Article metrics might have a role to play, but narra-
tive explanations of research significance and accom-
plishments would be more helpful.
3. Funders, universities, and other institutions should 
make it clear to their review committees that journal 
brand cannot be used as a proxy for scientific quality. If 
reviewers object, they should find different reviewers.
4. The scientists who serve as editors or editorial board 
members of journals could insist that the publishers of 
these journals stop promoting IFs. Instead, the journals 
could emphasize the other valuable services they provide 
to authors and readers to promote their worth to the 
community.
Schekman points out that no doubt others will come up with 
bigger, better, and maybe even bolder ideas to move science 
away from the problems it is currently facing. He hopes that 
his words have helped spark a discussion, but now is the time 
to turn attention to action [15].
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